close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.08 +1.59 (+1.82%)
Streaming Delayed Price Updated: 3:31 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,207,608
Open 88.19
Bid (Size) 89.07 (300)
Ask (Size) 89.08 (300)
Prev. Close 87.48
Today's Range 88.00 - 89.27
52wk Range 61.24 - 87.53
Shares Outstanding N/A
Dividend Yield 1.16%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why AstraZeneca Stock Was a Winner Today
The company inches closer to bringing a new drug to a very large addressable market. 
Via The Motley Fool
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence

Performance

YTD
+35.2%
+35.2%
1 Month
+5.4%
+5.4%
3 Month
+20.3%
+20.3%
6 Month
+29.2%
+29.2%
1 Year
+37.5%
+37.5%

More News

Read More
AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial
Via Benzinga
Earnings Scheduled For November 6, 2025
Via Benzinga
Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs
Via Stocktwits
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
From AstraZeneca
Via Business Wire
3 Reasons to Buy IonQ Stock Like There's No Tomorrow
Via The Motley Fool
Topics Artificial Intelligence Fraud
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease
From AstraZeneca
Via Business Wire
Why AstraZeneca Stock Topped the Market on Thursday
Via The Motley Fool
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
Via Benzinga
Topics Government
AstraZeneca Calms Pricing Jitters, Says US Deal Hit Absorbable
Via Benzinga
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday?
Via Benzinga
Topics Artificial Intelligence
AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar
Via Investor's Business Daily
AstraZeneca's 9M and Q3 2025 Financial Results
From AstraZeneca
Via Business Wire
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence
Snowflake And SAP Bridge Enterprise Data Silos In Major AI Integration Push
Via Benzinga
Topics Artificial Intelligence
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
Via Investor's Business Daily
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Via MarketMinute
Topics Government World Trade
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
Via MarketBeat

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 89.08
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 11/11/25 03:31 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today